PS
CPRX

Principal Securities’s Catalyst Pharmaceutical CPRX Stock Holding History

Principal Securities’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-38
Closed -$749 – 1771
2025
Q3 		$749 Sell
38
-1,839
-98% -$37.8K ﹤0.01% 3464
2025
Q2 		$40.7K Buy
1,877
+1,024
+120% +$24.2K ﹤0.01% 1977
2025
Q1 		$17.8K Hold
853
– – ﹤0.01% 2265
2024
Q4 		$17.8K Buy
853
+801
+1,540% +$17.2K ﹤0.01% 2263
2024
Q3 		$1.03K Buy
52
+24
+86% +$445 ﹤0.01% 3132
2024
Q2 		$434 Hold
28
– – ﹤0.01% 3225
2024
Q1 		$446 Sell
28
-1,246
-98% -$18.8K ﹤0.01% 3160
2023
Q4 		$21.4K Buy
+1,274
New +$17.4K ﹤0.01% 1888

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Principal Securities's CPRX Position: Q4 2025 in Review

Principal Securities sold out of Catalyst Pharmaceutical (CPRX) in Q4 2025, closing a stake of 38 shares — an estimated $749 sold.

Principal Securities first reported a position in CPRX in Q4 2023 and held it in 8 quarters. The position peaked at $40.7K in Q2 2025. 373 funds tracked by Wall St. Rank hold CPRX as of Q4 2025.

  • Principal Securities reported no remaining Catalyst Pharmaceutical position as of Q4 2025 after selling out during the quarter.
  • Principal Securities sold 38 Catalyst Pharmaceutical shares in Q4 2025, an estimated $749.
  • Principal Securities first reported a position in Catalyst Pharmaceutical in Q4 2023 and held it in 8 quarters.
  • Principal Securities's Catalyst Pharmaceutical position peaked at $40.7K in Q2 2025.
  • 373 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.